

RealRate

PHARMACEUTICAL 2022

SYBLEU Inc Rank 8 of 466







PHARMACEUTICAL 2022

SYBLEU Inc Rank 8 of 466

The relative strengths and weaknesses of SYBLEU Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SYBLEU Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 155% points. The greatest weakness of SYBLEU Inc is the variable Other Expenses, reducing the Economic Capital Ratio by 84% points.

The company's Economic Capital Ratio, given in the ranking table, is 314%, being 236% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	14
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	31
Liabilities, Non-Current	0
Other Assets	185
Other Compr. Net Income	0
Other Expenses	114
Other Liabilities	0
Other Net Income	7.8
Other Revenues	177
Property and Equipment	0
Research and Development	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	200
Liabilities	31
Expenses	114
Revenues	177
Stockholders Equity	169
Net Income	72
Comprehensive Net Income	72
Economic Capital Ratio	314%

